Carcinoid syndrome natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 17: Line 17:


==Prognosis==
==Prognosis==
*Factors that determine the clinical course and outcome of patients with GI carcinoid tumors are complex and multifaceted and include the following:
:*The site of origin
:*The size of the primary tumor
:*The anatomical extent of disease
*Elevated expression of the proliferation antigen Ki-67 and the tumor suppressor protein p53 have been associated with poorer prognosis
*Adverse clinical prognostic indicators include:
:*Carcinoid syndrome
:*Carcinoid heart disease
:*High concentrations of the tumor markers urinary 5-HIAA and plasma chromogranin A
The outlook in patients with carcinoid syndrome is different from the outlook in patients who have carcinoid tumors without the syndrome.
The outlook in patients with carcinoid syndrome is different from the outlook in patients who have carcinoid tumors without the syndrome.
In people with the syndrome, the tumor has usually spread to the liver, which lowers the survival rate. People with carcinoid syndrome are also more likely to have a separate cancer (second primary tumor) at the same time.
In people with the syndrome, the tumor has usually spread to the liver, which lowers the survival rate. People with carcinoid syndrome are also more likely to have a separate cancer (second primary tumor) at the same time.

Revision as of 17:14, 17 September 2015

Carcinoid syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carcinoid Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carcinoid syndrome natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carcinoid syndrome natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carcinoid syndrome natural history, complications and prognosis

CDC on Carcinoid syndrome natural history, complications and prognosis

Carcinoid syndrome natural history, complications and prognosis in the news

Blogs on Carcinoid syndrome natural history, complications and prognosis

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Prognosis varies from individual to individual. It ranges from a 95% 5 year survival for localized disease to a 20% 5 year survival for those with liver metastases. The average survival time from the start of octreotide treatment has increased to about 12 years.

Natural History

Complications

Prognosis

  • Factors that determine the clinical course and outcome of patients with GI carcinoid tumors are complex and multifaceted and include the following:
  • The site of origin
  • The size of the primary tumor
  • The anatomical extent of disease
  • Elevated expression of the proliferation antigen Ki-67 and the tumor suppressor protein p53 have been associated with poorer prognosis


  • Adverse clinical prognostic indicators include:
  • Carcinoid syndrome
  • Carcinoid heart disease
  • High concentrations of the tumor markers urinary 5-HIAA and plasma chromogranin A

The outlook in patients with carcinoid syndrome is different from the outlook in patients who have carcinoid tumors without the syndrome. In people with the syndrome, the tumor has usually spread to the liver, which lowers the survival rate. People with carcinoid syndrome are also more likely to have a separate cancer (second primary tumor) at the same time. The outlook is more favorable with new treatment methods, such as Sandostatin.

References


Template:WikiDoc Sources